Home
|
Inbox
|
Search
|
View Abstract
Efficacy of a Home Discharge Care Bundle After Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A2766 - Efficacy of a Home Discharge Care Bundle After Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Author Block: S. Cousse, M. Salaün, L. Thiberville, A. Cuvelier, M. Patout; Pulmonology, Thoracic Oncology, and Respiratory Intensive Care, CHU de Rouen, Rouen, France.
RATIONALE: Acute exacerbations of COPD (AECOPD) are frequent and are associated with a poor prognosis. A home discharge care bundle, the PRADO-BPCO program, has been set up by the French National Health system in order to reduce readmission rate after hospitalization for AECOPD. This program includes early consultation by the general practitioner, a nurse and a physiotherapist. The aim of our study was to evaluate the effect of the PRADO-BPCO program on the readmission rate of COPD patients at 28 days after hospitalization for AECOPD.
METHODS: This is a retrospective case-control study including all patients admitted for AECOPD to the Rouen University Hospital between November 2015 and January 2017. The re-admission or death rate at 28 days after hospitalization for AECOPD was compared between patients included in the PRADO-BPCO program and patients with standard care after discharge. Inclusion in the PRADO-BPCO program was decided by the physician in charge of the patient.
RESULTS: There was 294 admissions for AECOPD during the study period: 62 (21.4%) were included in the PRADO-BPCO group at baseline, patients in the PRADO group had more severe COPD and had more severe exacerbations than the control group. Inpatient stay was shorter in the PRADO group: 8.6±4.3 days vs. 10.4±7.4 (p=0.034). Readmission or death rate at 28-days was similar between groups: 16.1% in the PRADO group vs. 14.4% in the control group (p=0.73). Ninety-days readmission or death rate, as well as overall survival were similar in the 2 groups.
CONCLUSION: In our centre, despite more severe COPD and a shorter hospitalization time, patients in the PRADO-BPCO program had the same re-admission or death rate at 28 days as compared to standard care.
Author Block: S. Cousse, M. Salaün, L. Thiberville, A. Cuvelier, M. Patout; Pulmonology, Thoracic Oncology, and Respiratory Intensive Care, CHU de Rouen, Rouen, France.
RATIONALE: Acute exacerbations of COPD (AECOPD) are frequent and are associated with a poor prognosis. A home discharge care bundle, the PRADO-BPCO program, has been set up by the French National Health system in order to reduce readmission rate after hospitalization for AECOPD. This program includes early consultation by the general practitioner, a nurse and a physiotherapist. The aim of our study was to evaluate the effect of the PRADO-BPCO program on the readmission rate of COPD patients at 28 days after hospitalization for AECOPD.
METHODS: This is a retrospective case-control study including all patients admitted for AECOPD to the Rouen University Hospital between November 2015 and January 2017. The re-admission or death rate at 28 days after hospitalization for AECOPD was compared between patients included in the PRADO-BPCO program and patients with standard care after discharge. Inclusion in the PRADO-BPCO program was decided by the physician in charge of the patient.
RESULTS: There was 294 admissions for AECOPD during the study period: 62 (21.4%) were included in the PRADO-BPCO group at baseline, patients in the PRADO group had more severe COPD and had more severe exacerbations than the control group. Inpatient stay was shorter in the PRADO group: 8.6±4.3 days vs. 10.4±7.4 (p=0.034). Readmission or death rate at 28-days was similar between groups: 16.1% in the PRADO group vs. 14.4% in the control group (p=0.73). Ninety-days readmission or death rate, as well as overall survival were similar in the 2 groups.
CONCLUSION: In our centre, despite more severe COPD and a shorter hospitalization time, patients in the PRADO-BPCO program had the same re-admission or death rate at 28 days as compared to standard care.
|
Home
|
Inbox
|
Search
|